A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

NCT06178601 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: RC48-ADC
DRUG: AK104

Sponsor

Shanxi Province Cancer Hospital

Collaborators

[object Object]